Adverse Reactions in a Phase 1 Trial of the Anti-Malarial DM1157: An Example of Pharmacokinetic Modeling and Simulation Guiding Clinical Trial Decisions.

Balevic SJ, Raja SM, Randell R, Deye GA, Conrad T, Nakamura A, Peyton DH, Shotwell S, Liebman K, Cohen-Wolkowiez M, Guptill JT

Open source

DOI
10.1007/s40121-022-00605-z
Published
2022 Apr
Container
Infectious diseases and therapy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s40121-022-00605-z,
  title = {Adverse Reactions in a Phase 1 Trial of the Anti-Malarial DM1157: An Example of Pharmacokinetic Modeling and Simulation Guiding Clinical Trial Decisions.},
  author = {Balevic SJ and Raja SM and Randell R and Deye GA and Conrad T and Nakamura A and Peyton DH and Shotwell S and Liebman K and Cohen-Wolkowiez M and Guptill JT},
  year = {2022},
  journal = {Infectious diseases and therapy},
  doi = {10.1007/s40121-022-00605-z},
  url = {https://doi.org/10.1007/s40121-022-00605-z}
}

RIS

TY  - JOUR
TI  - Adverse Reactions in a Phase 1 Trial of the Anti-Malarial DM1157: An Example of Pharmacokinetic Modeling and Simulation Guiding Clinical Trial Decisions.
AU  - Balevic SJ
AU  - Raja SM
AU  - Randell R
AU  - Deye GA
AU  - Conrad T
AU  - Nakamura A
AU  - Peyton DH
AU  - Shotwell S
AU  - Liebman K
AU  - Cohen-Wolkowiez M
AU  - Guptill JT
PY  - 2022
JO  - Infectious diseases and therapy
DO  - 10.1007/s40121-022-00605-z
UR  - https://doi.org/10.1007/s40121-022-00605-z
ER  - 

APA

SJ, B., SM, R., R, R., GA, D., T, C., A, N., DH, P., S, S., K, L., M, C., & JT, G. (2022). Adverse Reactions in a Phase 1 Trial of the Anti-Malarial DM1157: An Example of Pharmacokinetic Modeling and Simulation Guiding Clinical Trial Decisions.. Infectious diseases and therapy. https://doi.org/10.1007/s40121-022-00605-z

Source records